Company research
Sionna Therapeutics, Inc.
CIK 2036042Updated Sep 27, 2026
SecuritySION · NASDAQ · equity
SION price & chart
Loading TradingView…
NASDAQ:SION on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation.…
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION ↗
Recent filings
SCHEDULE 13D/A - filed by RA CAPITAL MANAGEMENT, L.P. regarding Sionna Therapeutics, Inc.
4 filing
4 filing
4 filing
4 filing
Show 5 more recent filings
144 filing
Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 2.05, 5.02, 8.01, 9.01
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 325,953,000Source | 185,752,000Source |
| Property, Plant and Equipment, NetUSD | 2,225,000Source | 2,466,000Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 58,451,000Source | 37,788,000Source |
| Assets, CurrentUSD | 241,419,000Source | 150,993,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,537,000Source | 3,455,000Source |
| Operating Lease, Right-of-Use AssetUSD | 6,926,000Source | 7,832,000Source |
| Other Assets, NoncurrentUSD | 0Source | 2,994,000Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 19,120,000Source | 19,097,000Source |
| Stockholders’ equity: | ||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 45,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 562,602,000Source | 17,000,000Source |
| Retained Earnings (Accumulated Deficit)USD | -256,354,000Source | -181,086,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 540,000Source | 368,000Source |
| Stockholders' Equity Attributable to ParentUSD | 306,833,000Source | -163,713,000Source |
| Liabilities and EquityUSD | 325,953,000Source | 185,752,000Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 11,712,000Source | 10,420,000Source |
| Operating Lease, Liability, CurrentUSD | 1,269,000Source | 1,072,000Source |
| Operating Lease, Liability, NoncurrentUSD | 7,408,000Source | 8,677,000Source |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 9,668,000Source | 8,162,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 12,066,000Source | 3,708,000Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts PayableUSD | -417,000Source | 467,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -66,297,000Source | -52,787,000Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -118,749,000Source | -126,913,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 377,000Source | 27,000Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 205,710,000Source | 178,967,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 20,664,000Source | -733,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 59,414,000Source | 38,750,000Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 12,066,000Source | 3,708,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source |
| DepreciationUSD | 647,000Source | 668,000Source |
| General and Administrative ExpenseUSD | 28,719,000Source | 13,268,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Investment Income, InterestUSD | 13,295,000Source | 8,170,000Source |
| Net Income (Loss) Attributable to ParentUSD | -75,268,000Source | -61,688,000Source |
| Nonoperating Income (Expense)USD | 13,714,000Source | 8,868,000Source |
| Operating ExpensesUSD | 88,982,000Source | 70,556,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 206,653,000Source | 55,955,000Source |
| Proceeds from Stock Options ExercisedUSD | 3,639,000Source | 141,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Operating Income (Loss)USD | -88,982,000Source | -70,556,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -75,268,000Source | -61,688,000Source |
| Earnings Per Share, BasicUSD per share | -1.88Source | -15.99Source |
| Earnings Per Share, DilutedUSD per share | -1.88Source | -15.99Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 39,962,163Source | 3,858,859Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 39,962,163Source | 3,858,859Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 28,719,000Source | 13,268,000Source |
| Investment Income, InterestUSD | 13,295,000Source | 8,170,000Source |
| Nonoperating Income (Expense)USD | 13,714,000Source | 8,868,000Source |
| Operating ExpensesUSD | 88,982,000Source | 70,556,000Source |
| Research and Development ExpenseUSD | 60,263,000Source | 57,288,000Source |
Offerings
Registration 333-284352
- Gross proceeds
- 190588194.0
- Net proceeds
- 177247020.0
- Deal price
- 18.0
- Shares
- 10588233
- Offering price
- $18.00
- Ticker
- SION
Filing attachments
d148638dex991.htm · 8-K · 2026-09-14
EX-99.1 2 d148638dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to initiate in first quarter of 2027 46% workforce reduction and other cost-saving measures prioritiz…
Read attachment ↗d135438dex991.htm · 8-K · 2026-08-10
EX-99.1 2 d135438dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care Potential confounders in SION-719 Phase 2a trial are being evaluated to inform next steps for the SION-451 du…
Read attachment ↗d944102dex991.htm · 8-K · 2025-06-04
EX-99.1 2 d944102dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add…
Read attachment ↗d679677dex991.htm · 8-K · 2025-03-20
EX-99.1 2 d679677dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025 On track to initiate NBD1 Phase 2a proof-of-concept trial in combination with SOC in CF patients and combination MAD …
Read attachment ↗d882384dex41.htm · S-1 · 2025-01-17
EX-4.1 4 d882384dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Sionna Therapeutics (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby,…
Read attachment ↗d882384dex42.htm · S-1 · 2025-01-17
EX-4.2 5 d882384dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of March 4, 2024, by and among Sionna Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREAS, the Company and certain of the Investors are parties to that certain …
Read attachment ↗